skip to page content

Homology Medicines Convenes Panel on Developing Genetic Medicines for Patients at BIO International Convention

BEDFORD, Mass., June 4, 2018 – Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Sam Rasty, Ph.D., Chief Operating Officer, will moderate the panel, “Making Genetic Therapies a Reality for Patients,” during the 2018 BIO International Convention at 4:15 p.m. ET on Wednesday, June 6, 2018 at the Boston Convention & Exhibition Center.

The panel of experts will provide perspective on how different functions work together, including scientific, clinical, commercial and finance, to bring a new treatment forward for patients. The speakers include:

  • Emmanuel Dulac, PharmD, Ph.D., Chief Commercial Officer, Alnylam Pharmaceuticals
  • Katherine High, M.D., President and Head of R&D, Spark Therapeutics
  • Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio
  • David Williams, M.D., Chief Scientific Officer and Senior Vice President for Research, Boston Children’s Hospital

About Homology Medicines, Inc.
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated  virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing  therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit

Investor Contact:
Theresa McNeely
SVP, Corporate Communications and Patient Advocacy

Media Contact:
Cara Mayfield
Senior Director, Patient Advocacy and Corporate Communications